Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mohammad Bagher Majnooni
 -- 3177 2023-03-21 21:27:36 |
2 format change
Peter Tang
Meta information modification 3177 2023-03-22 03:22:22 | |
3 format change
Peter Tang
Meta information modification 3177 2023-03-24 07:51:28 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Majnooni, M.B.; Fakhri, S.; Ghanadian, S.M.; Bahrami, G.; Mansouri, K.; Iranpanah, A.; Farzaei, M.H.; Mojarrab, M. Inhibiting Angiogenesis by Anti-Cancer Saponins. Encyclopedia. Available online: https://encyclopedia.pub/entry/42407 (accessed on 03 July 2024).
Majnooni MB, Fakhri S, Ghanadian SM, Bahrami G, Mansouri K, Iranpanah A, et al. Inhibiting Angiogenesis by Anti-Cancer Saponins. Encyclopedia. Available at: https://encyclopedia.pub/entry/42407. Accessed July 03, 2024.
Majnooni, Mohammad Bagher, Sajad Fakhri, Syed Mustafa Ghanadian, Gholamreza Bahrami, Kamran Mansouri, Amin Iranpanah, Mohammad Hosein Farzaei, Mahdi Mojarrab. "Inhibiting Angiogenesis by Anti-Cancer Saponins" Encyclopedia, https://encyclopedia.pub/entry/42407 (accessed July 03, 2024).
Majnooni, M.B., Fakhri, S., Ghanadian, S.M., Bahrami, G., Mansouri, K., Iranpanah, A., Farzaei, M.H., & Mojarrab, M. (2023, March 21). Inhibiting Angiogenesis by Anti-Cancer Saponins. In Encyclopedia. https://encyclopedia.pub/entry/42407
Majnooni, Mohammad Bagher, et al. "Inhibiting Angiogenesis by Anti-Cancer Saponins." Encyclopedia. Web. 21 March, 2023.
Inhibiting Angiogenesis by Anti-Cancer Saponins
Edit
This entry is adapted from the peer-reviewed paper 10.3390/metabo13030323

Saponins are one of the broadest classes of high-molecular-weight natural compounds, consisting mainly of a non-polar moiety with 27 to 30 carbons and a polar moiety containing sugars attached to the sapogenin structure. Saponins are found in more than 100 plant families as well as found in marine organisms. Saponins have several therapeutic effects, including their administration in the treatment of various cancers. These compounds also reveal noteworthy anti-angiogenesis effects as one of the critical strategies for inhibiting cancer growth and metastasis.

triterpenoid saponins steroidal saponins angiogenesis VEGF HIF-1α inflammation signaling pathways

1. Introduction

Saponins are one of the most widespread secondary metabolites presents in the plant kingdom and marine organisms, generating stable foam in aqueous solutions, such as soap [1]. Humans have long used saponin-rich plants in their diets to maintain health and therapeutic benefits, including some Fabaceae plants [2], such as pea (Pisum sativum), beans (Phaseolus spp.), fava bean (Vicia faba), soybean (Glycine max), mung bean (Vigna radiate), and licorice (Glycyrrhiza glabra). Additionally, Allium genus plants [3] are also rich in saponins, such as garlic (Allium sativum), onion (Allium cepa), and chives (Allium schoenoprasum). Moreover, herbs, including tea (Camellia sinensis), banana (Musa spp.), and ginseng (Panax ginseng), are found as saponin sources [4]. Saponins are composed of two parts, including aglycone (sapogenin) as non-polar moiety and glycoside (saccharide chain) as polar moiety. Triterpenoid saponins and steroidal saponins with, respectively, 30 and 27 carbon atoms, are the 2 main chemical structures of sapogenin core of saponins isolated from natural sources [5]. Furthermore, farnesyl diphosphate synthesized from the mevalonate biosynthetic pathway is the main precursor of the sapogenin [6][7]. Saponins have a high structural diversity due to the presence of functional groups on the sapogenin core, the number and type of sugars in the structure, and the way sugars bind to each other and to the aglycone part. Such structural diversity causes various biological and pharmacological effects [8]. Accordingly, several effects have been reported for saponins, such as anti-microbial, anti-leishmaniasis, anti-oxidant, anti-cholesterol, anti-lipidemia, analgesic, anti-inflammation, anti-diabetic, and anti-coagulant effects. [1][9]. Saponins also revealed the prominent anti-cancer and cytotoxic activities via regulating multiple signal pathways of cellular apoptosis, cell cycle arrest, proliferation, autophagy, and inflammation [10].
Angiogenesis, as the formation of new blood vessels, is one of the most important strategies to provide the energy needed for the survival and proliferation of cancer cells. Today, the inhibition of angiogenesis is used as a new and practical idea to control the growth and metastasis of tumors [11]. Since the discovery of the significant role of angiogenesis in the growth and progression of tumors by Folkman in 1971 [12], several drugs with anti-angiogenic effects have been introduced to the global pharmaceutical market, including bevacizumab, lenalidomide, axitinib, sorafenib, and everolimus. These drugs treat cancer by inhibiting the angiogenesis triggers, including the vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-α (HIF-1α) release [13]. On the other hand, plants and their secondary metabolites have always been considered by researchers to treat cancer. According to investigations, plant secondary metabolites have also had a significant effect on inhibiting the growth and progression of tumors through blocking angiogenesis stimulation cellular signaling pathways [14]. Vinca alkaloids and paclitaxel, which have been isolated from Catharanthus roseus (Apocynaceae) and Taxus brevifolia (Taxaceae), respectively, are among anti-angiogenesis natural products found in pharmaceutical markets [15].
Sobolewska et al. reviewed the cytotoxic effects and anti-cancer mechanisms of saponins emphasizing the structure-activity relationship and their natural sources [16][17]. In this present research, the dramatic effects of saponins have been described on inhibiting the growth and metastasis of cancer via inhibiting the gene expression of angiogenesis mediators, including VEGF/VEGFR2, HIF-1α, fibroblast growth factor 2 (FGF2), and phosphoinositide 3-kinases/protein kinase B (PI3K/Akt). The anti-cancer effects of saponin was also shown to be applied through blocking inflammatory cellular signaling pathways, including pro-inflammatory cytokines, mitogen-activated protein kinase (MAPKs) pathways, and nuclear factor κ light chain enhancer of activated B cells (NF-κB).

2. Angiogenesis: Cellular Signaling Pathways

The angiogenic process is a complex and extremely regulated action that enhances tumor progression and survival. Several signaling pathways and interconnected mediators are involved in the pathogenesis of angiogenesis that could be controlled through modulating multiple autophagy, oxidative stress, inflammatory, apoptotic pathways, and proangiogenic/antiangiogenic markers [18]. Pro-angiogenic mediators could be released through different kinds of cells, including endothelial cells (ECs), smooth muscle cells, fibroblasts, immune cells, platelets, and tumor cells [18][19]. The pro-angiogenic-signaling molecule VEGF and its cognate receptor, tyrosine kinase VEGF receptor 2 (VEGFR2), play a vital role in angiogenesis [20][21]. Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), angiopoietins, ephrins, apelin (APLN), granulocyte and granulocyte/macrophage colony-stimulating factors (G-CSF and GM-CSF), hepatocyte growth factor/scatter factor (HGF/SF), and inflammatory factors, including cytokines, such as interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α (TNF-α), and chemokines are among other pro-angiogenic agents [19][21][22][23][24][25]. Inflammation is one of the main lethal factors in angiogenesis and cancer, which cause DNA damages through several macrophage migration inhibitory factor (MIF) and reactive oxygen species (ROS) and reactive nitrogen species (RNS) production [26]. These mediators contribute to the angiogenesis through the upregulation of transcription factors, such as MAPKs, NF-κB, signal transducer and activator of transcription 3 (STAT3), and mammalian target of rapamycin (mTOR). Recent studies demonstrated MAPK-signaling cascade and its main subfamilies, such as extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 plays pivotal roles in inflammation/oxidative stress-associated angiogenesis. Besides phosphatases and tensin homolog (PTEN)/PI3K/Akt/mTOR, Janus kinase (JAK)/STAT and Ras/Raf/mitogen-activated protein kinase (MEK)/ERK/MAPK signaling pathways are also interconnected with the modulation of inflammation, oxidative stress, and cancer cells survival [27][28][29][30][31][32][33]. Oxidative stress is another trigger of angiogenesis that linked with aforementioned signaling pathways. Oxidative stress is caused by an imbalance between ROS/RNS production and antioxidants factors, including catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione (GSH) [34]. Angiogenic inhibitors, including angioarrestin, angiostatin, endostatin, tumstatin, fibronectin fragment, IL-1, IL-12, interferons, canstatin, retinoic acid, arrestin, tissue inhibitors of metalloproteinases (TIMPs), multimerin 2, and angiogenic activators act together to maintain the balance of angiogenesis [13][19][23][35][36][37]. Angiogenesis is accomplished when stimulating factors, such as VEGF, angiopoietin-1 (ANG-1), and placental growth factor (PLGF), permeabilize the vessels. These factors also involved in the formation of new vessels. In addition, angiopoietin, angiogenin, TGF α/β, and matrix metalloproteinases (MMPs) are among other angiogenic stimulators [35][38][39]. Moreover, recent studies showed microRNAs (miRNAs) play a significant role in metabolism, apoptosis, protein secretion, cell proliferation, division, and differentiation that could modulate different stages of angiogenesis by targeting numerous genes within various signaling pathways. Thus, they could be new therapeutic targets in regulating angiogenesis [40]. In addition, hypoxia disrupts the balance between pro-angiogenic and antiangiogenic factors leading to the upregulation of HIF-1α, which suppresses antiangiogenic factors expression while promoting the pro-angiogenesis factors expression [19][41]. HIF-1α is the main stimulus for elevated VEGF, FGF, and PDGF production in cancer [23]. Hence, all the markers in the aforementioned signaling pathways could be considered effective therapeutic targets in angiogenesis.

3. Targeting Tumor Cells with Anti-Angiogenic Agents: Recent Advances

To stop angiogenesis, it is necessary to use anti-angiogenic factors or agents that decrease the production of pro-angiogenic markers, prevent them from binding to their receptors, or stop their functions [42]. Monoclonal antibodies (mAbs), small molecule inhibitors, VEGF inhibitors, tyrosine kinase inhibitors, gene therapy, and RNA interference (RNAi) therapy are auspicious anti-angiogenic interventions [19][43][44]. VEGF/VEGFR and interconnected downstream pathways have been the crucial targets of anti-angiogenic drugs. Small molecules inhibitors and mAbs modulating cell growth, differentiation, and angiogenesis through targeting VEGFRs, FGF receptors (FGFRs), EGFR receptors (EGFRs), PDGF receptors (PDGFR-α, PDGFR-β), Fms-like tyrosine kinase 3, and signaling proteins, including Raf, MAPK, mTOR, and PI3K [19][42][43][44]. Bevacizumab, aflibercept, and ramucirumab are monoclonal antibodies that exert anti-angiogenic effects by targeting the VEGF/VEGFR signaling pathway [21][43][44][45]. Receptor tyrosine kinase inhibitor small molecules (RTKIs) suppress signals inside blood vessels cells and are active against a numerous range of receptors involved in angiogenesis, including VEGFR, PDGFR, FGFR, rearranged during transfection (RET), and Tie receptors [43]. Sorafenib and sunitinib are among RTKIs that block angiogenesis and tumor growth via targeting the RAF/MEK/ERK signaling pathway, VEGFR-2, PDGFRB, and colony-stimulating factor-1 (CSF-1) [43][44]. The angiopoietins (Ang1–4)–Tie-axis is another pathway in angiogenesis. Ang1 and Ang2 expressions increased in many tumors. Ang1 binds to the Tie2 receptor and leads to a decline in vascular permeability and raised vessel stabilization, while Ang2 induces neovascularization and ECs migration and proliferation in response to pro-angiogenic markers [44][46][47]. Hence, a higher ratio of Ang1 to Ang2 predicts better outcomes. Trebananib showed promising antiangiogenics effects by targeting the Ang/Tie-axis in phase II trials [48]. Recent studies showed phytochemicals, such as alkaloids, saponins, tanshinone, coumarins, flavonoids and artemisinin, allow for the activity of modulating angiogenesis through regulating pro-angiogenic and anti-angiogenic factors [49][50]. In addition, vinca alkaloids (e.g., vinblastine, vincristine, vinorelbine, and vindesine), podophyllotoxin and its derivations (e.g., irinothecan, topothecan), taxanes (e.g., docetaxel, paclitaxel), camptothecins, and anthracyclines (e.g., daunorubicin, idarubicin, doxorubicin, and epirubicin) are effective herbal medicines on angiogenesis/cancer [19][24][49][50][51]. In recent decades, natural products have attracted great interest in combating tumor angiogenesis due to their fewer side effects and multi-functional mechanisms of action. Therefore, natural products and phytochemicals could be promising sources for the prevention or/and treatment of cancer.

4. Saponins

4.1. Chemistry, Biosynthesis, and Natural Sources

Saponins are a large group of secondary metabolites that are abundant in natural sources, including plants and marine organisms. These compounds have a high molecular weight, containing 27–30 carbons (C). In their structure, C3 is bound to the hydroxyl group in all aglycone saponins [52]. Saponins possess a polar/non-polar structure. In their polar sections, saponins have sugar chains (glycosylated forms), while the sapogenin structure makes the nonpolar part. Such chemical properties cause soap-like foams behaviors in aqueous solutions for saponins [53].
Squalene and 2,3-oxidosqualene are critical precursors in the biosynthesis of saponins. Accordingly, two units of farnesyl pyrophosphate formed in the mevalonate biosynthetic pathway and converted to squalene in the presence of the enzyme squalene synthase. The produced squalene is then converted to 2,3-oxidosqualene by the squalene epoxidase enzyme. Consequently, squalene and 2,3-oxidosqualene are converted to various aglycone saponins by different enzymes, cyclase and cytochrome P450. Finally, aglycone saponins are glycosylated by glycosyltransferase enzymes [6][7][54] (Figure 1).
Figure 1. An overview on saponin biosynthesis pathway.
Saponins are typically divided into two main categories, including triterpenoid saponins (C30, Figure 2A) and steroidal saponins (C27, Figure 2B). However, alkaloidal saponins (Figure 2C), which contain nitrogen atoms, are also classified in this category [5][55]. Consequently, steroidal saponins are divided into three categories, including spirostanes, furostanes, and cholestanes or open-chain steroidal saponins (Figure 2B). The spirostanes have a common spiro-carbon at the junction of two heterocyclic rings of furan and pyran in their structure and A and B rings are mainly trans isomer. The A and B rings of furostanes are found in both the cis and trans isomeric position and mainly consist of four hydrocarbon rings attached to a furan ring. Consistently, cholestane steroids do not have O-heterocyclic rings, and there is an opened ring in this group of saponins [52][56].
Figure 2. Chemical structures of saponin cores. (A) Triterpenoid saponins, (B) Steroidal saponins, and (C) Alkaloidal saponins.
Oleananes and dammaranes (Figure 2A), with, respectively, five and four hydrocarbon rings, are two main groups of triterpenoid saponins isolated from natural sources, especially the plant kingdom. The terpenoid saponins rings are in an all-trans isomeric position. Additionally, their aglycone mostly contains functional groups including COOH, OH, and CH2OH at C28, C3, and C24, respectively [5][53][57].
Natural sources-isolated saponins are in glycosylated form and contain various saccharide chains. These saccharide chains are mainly oligosaccharides and composed of Dextro (D) or Leavo (L) isomers of sugars, such as glucose, galactose, rhamnose, arabinose, xylose, and glucuronic acid. However, sugars, such as quinovose, apiose, and fucose, are also found at a lesser frequency [53][58][59][60][61]. According to the number of saccharide chains attached to the saponin structure, these compounds are divided into two main categories: monodsmosidic and bidesmosidic, although in limited cases, tridesmoside saponins are also seen [62]. Although steroid saponins are generally monodsmosidic and are usually attached to the sugar chain at the C3 position, terpenoid saponins are bidesmosidic. Furthermore, tridesmoside, and the sugar chains, in addition to C3, are attached to the functional groups in C28 and C24 carbon. However, in some cases, the saccharide chain may bind to other carbons in the saponins structure [63][64][65].
Saponins are widely found in more than 100 families of dicotyledonous and monocotyledonous plants. These compounds are presented in different parts of the plants, including leaves, stems, roots, flowers, bark, and fruits, accumulate and thereby play protective roles against herbivores, microorganisms, and environmental stresses such as drought stress and temperature changes [66][67]. Steroid saponins are mostly found in monocotyledonous plants, such as Dioscoreaceae, Asparagaceae, Liliaceae, and Amaryllidaceae. Dicotyledonous families, such as Fabaceae, Araliaceae, Quillajaceae, Polygalaceae, Caryophyllaceae, Primulaceae, and Theaceae, mostly contain terpenoid saponins. Alkaloidal saponins are also isolated from the Solanaceae family [56][68][69]. Several steroidal saponins, such as dioscin, gracillin, deltonin, and parrisaponin, are isolated from Dioscorea genus [68]. Patricia Y et al. isolated shatavarin V as a new spirostanol saponin from the Asparagus racemosus (Asparagaceae) root [70]. Sobolewska et al. have introduced more than 350 steroidal saponins from Allium species (Liliaceae) in their review article [52]. In another study, 10 new terpenoid saponins were separated from the root of Glycyrrhiza glabra (Fabaceae), such as 11-deoxorhaoglycyrrhizin, 30-hydroxyglycyrrhizin, and 20α-rhaoglycyrrhizin [71]. Additionally, more than 100 saponins were isolated from Quillaja saponaria bark (Quillajaceae), with quillaic acid and its derivatives among the most well-known [72]. Panax ginseng (Araliaceae) is one of the rich sources of dammarane-type saponins, including ginsenoside derivatives [73]. Due to the presence of two or three hydroxyl groups in the chemical structure of ginsenosides, they are categorized into two main groups, including protopanaxadiol (Rb1, Rb2, Rg3, Rc, Rd, and Rh2) and protopanaxatriols (ginsenoside Rg1, Rg2, Rg3, Re, and Rh) [74][75]. Furthermore, nowadays, sea organisms, such as sea cucumbers, starfish, and sponges, have attracted the attention of researchers as rich sources of saponins [76][77][78]. Bahrami et al. isolated and identified 89 types of saponins, including terpenoid saponins, Holothurinoside and Holothurin derivatives, from a species of sea cucumber (Holothuria lessoni) [79].
In summary, due to their unique chemical structure and structural diversity, saponins have shown a bright future among natural compounds.

4.2. Pharmacological and Biological Activities

The structural diversity of saponins have led to their various biological and pharmacological effects. In addition to their biological effects, such as cytotoxicity [17], antibacterial [80][81], anti-viral [82], anti-fungal [83][84], anti-leishmania [85][86], anti-inflammation [87][88], and anti-oxidant [89][90] mechanisms, saponins have shown prominent pharmacological effects, such as cardioprotective [91], neuroprotective [92], anti-cancer [93][94], hepatoprotective [95], wound healing [96][97], analgesic [98][99], anti-rheumatoid [100][101] anti-convulsant [102] and immunomodulatory [103][104] activities. More recently, saponins have also been used as adjuvants in vaccines [105][106]. QS-21, isolated from Quillaja saponaria bark (Quillajaceae), is one of the saponins that has passed clinical trials in different phases for use as an adjuvant in vaccination [107]. Accordingly, studies showed the beneficial therapeutic effects of saponins on various diseases, including metabolic diseases, such as obesity [108][109], diabetes [110][111], hypercholesterolemia [112], hypertension [113][114], and osteoporosis [115].
Dutta et al. showed that rasmuside A, as a steroidal saponin isolated from Asparagus racemosus fruits, had an anti-leishmaniasis effect on the Leishmania donovani strain at 1.31 ug/mL [116]. The saponin-rich fraction of green tea seeds (Camellia sinensis, Theaceae) showed significant anti-bacterial effects against Escherichia coli, Staphylococcus aureus and Salmonella spp. via the penetration and destruction of the bacterial cell membrane/wall [117]. Another study showed anti-oxidant and anti-inflammation activities for Camellia sinensis root saponins [118]. Aginoside, as a spirostane saponin isolated from Allium nigrum (Liliaceae) bulbs, showed strong anti-fungal activities at 400 ppm against wild fungi, such as Fusarium spp., that invade plants [119]. Moreover, Li et al. showed that the saponin-rich extract of Panax ginseng steamed root ameliorated the ischemic injuries at 200 mg/kg and 400 mg/kg, orally via modifying the hemodynamic parameters, such as the left ventricular systolic pressure and heart rate, as well as a decreasing of the intracellular calcium ion overload [120]. Additionally, a clinical study has been designed on the healing effects of Panax notoginseng saponins on patients with hypertensive intracerebral hemorrhage (NCT02999048). Onjisaponin derivatives, as the triterpenoid saponins isolated from Polygala tenuifolia root (Polygalaceae), showed prominent neuroprotective effects and increased the survival of PC21 cell lines against glutamate-induced neurotoxicity [121]. Additionally, Meng et al. showed in vitro (0.5, 1, and 2.5 μM) and in vivo (2.5 mg/kg, 5 mg/kg, and 10 mg/kg, intragastrically, rats) potentials of Paris saponin VII as a steroidal saponin separated and purified from the rhizome of Trillium tschonoskii Maxim (Melanthiaceae). In their study, Paris saponin VII ameliorated rheumatoid arthritis by inhibiting the expression of inflammatory signaling pathways, such as mitogen-activated protein kinase, and reducing inflammatory cytokines [100]. On the other hand, the saponin-rich extract of sea cucumber (Pearsonothuria graeff) revealed marked anti-obesity and anti-hyperlipidemia effects in the rat fed with 0.08% saponin-rich extract and a high-fat diet for eight weeks [122]. Macrophyllosaponin B and astragaloside VII, as two terpenoid saponins found in Astragalus spp., showed regulatory effects on the immune system at 60 μg/albino mice intraperitoneal (i.p.) via blocking the activities of interlukin-4 and stimulating the expression of interlukin-2 and interferon-γ [123]. The saponin-rich fraction of Clerodendrum infortunatum leaves (Lamiaceae) showed anti-convulsant effects at 45 mg/kg, i.p., and relieved the central and peripheral pain at 35 and 40 mg/kg, i.p., respectively, in mice [124]. In addition, several clinical trials have been conducted on the beneficial therapeutic effects of saponins and plants rich in saponins, such as onion (Allium cepa, Araliaceae) and fenugreek (Trigonella foenum-graecum, Fabaceae) [110][125][126][127][128]. So far, several clinical trials have been reported on the therapeutic effects of ginsenoside saponins on various diseases, including cardiovascular disorders, diabetes, blood lipids, high blood pressure, and obesity [129][130].
Furthermore, saponins have shown significant cytotoxic and anti-cancer activity through various mechanisms in in vivo and in vitro studies, which will be discussed in more detail in the next section. Overall, saponins have high therapeutic potential and could be introduced as promising candidates for the treatment of complex diseases, such as metabolic disorders and cancer.

4.3. An Overview on the Anti-Cancer Mechanisms of Saponins

According to the World Health Organization, cancer is rapidly spreading worldwide and has been the main cause of death in more than 60% of countries (112 out of 183 countries studied) in the world [131]. Therefore, researchers in the field of cancer are trying to find effective treatments for it. Due to their low side effects, multi-therapeutic targeting, and in most cases, their low-cost phytochemicals have been promising candidates for cancer treatment. Among the phytochemicals, saponins have been prominent anti-cancer candidates in vitro and in vitro [10][94].

4.4. Anti-Angiogenic Potentials

The inhibition of angiogenesis and direct killing of cancer cells are two main strategies in the treatment of cancer [132]. Ever since Folkman proposed the theory of angiogenesis inhibition for the treatment of cancer in 1971, many efforts have been made to find molecules with anti-angiogenic effects [12]. These investigations led to the introduction of some drugs, such as sorafenib, bevacizumab, sunitinib, everolimus, and axitinib, with anti-angiogenic effects in the treatment of various cancers [13]. Natural sources, especially phytochemicals, have been among the main candidates for the discovery of molecules with anti-angiogenic effects [133]. Alkaloid-based drugs (e.g., vincristine, vinblastine, and camptothecin) [134], terpenoid-based drugs (e.g., paclitaxel) [135], flavonoid-based drugs (e.g., naringenin, kaempferol, and hesperidin) [136], and coumarin-based drugs (e.g., galbanic acid, esculetin, and daphnetin) [19] are among the major phytochemicals reported to inhibit angiogenesis. Additionally, Saponins, as one of the largest groups of natural compounds, have shown notable anti-angiogenic effects in the treatment of various cancers, in vitro and in vivo.

References

  1. Osbourn, A.; Goss, R.J.M.; Field, R.A. The saponins—Polar isoprenoids with important and diverse biological activities. Nat. Prod. Rep. 2011, 28, 1261–1268.
  2. Singh, B.; Singh, J.P.; Singh, N.; Kaur, A. Saponins in pulses and their health promoting activities: A review. Food Chem. 2017, 233, 540–549.
  3. NajeebUllah, S.; Shinwari, Z.K.; Jan, S.A.; Khan, I.; Ali, M. Ethno medicinal and phytochemical properties of genus Allium: A review of recent advances. Pak. J. Bot. 2020, 53, 135–144.
  4. Rao, A.V.; Gurfinkel, D.M. Dietary Saponins and Human Health. In Saponins in Food, Feedstuffs and Medicinal Plants; Oleszek, W., Marston, A., Eds.; Springer: Dordrecht, The Netherlands, 2000; pp. 255–270.
  5. Vincken, J.-P.; Heng, L.; de Groot, A.; Gruppen, H. Saponins, classification and occurrence in the plant kingdom. Phytochemistry 2007, 68, 275–297.
  6. Seki, H.; Tamura, K.; Muranaka, T. P450s and UGTs: Key Players in the Structural Diversity of Triterpenoid Saponins. Plant Cell Physiol. 2015, 56, 1463–1471.
  7. Upadhyay, S.; Jeena, G.S.; Shikha; Shukla, R.K. Recent advances in steroidal saponins biosynthesis and in vitro production. Planta 2018, 248, 519–544.
  8. Moses, T.; Papadopoulou, K.K.; Osbourn, A. Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 439–462.
  9. Lacaille-Dubois, M.; Wagner, H. A review of the biological and pharmacological activities of saponins. Phytomedicine 1996, 2, 363–386.
  10. Elekofehinti, O.; Iwaloye, O.; Olawale, F.; Ariyo, E. Saponins in Cancer Treatment: Current Progress and Future Prospects. Pathophysiology 2021, 28, 250–272.
  11. Lopes-Coelho, F.; Martins, F.; Pereira, S.; Serpa, J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int. J. Mol. Sci. 2021, 22, 3765.
  12. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182–1186.
  13. Rajabi, M.; Mousa, S.A. The Role of Angiogenesis in Cancer Treatment. Biomedicines 2017, 5, 34.
  14. Lu, K.; Bhat, M.; Basu, S. Plants and their active compounds: Natural molecules to target angiogenesis. Angiogenesis 2016, 19, 287–295.
  15. Fakhri, S.; Abbaszadeh, F.; Jorjani, M.; Pourgholami, M.H. The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: A review study. Nutr. Cancer 2019, 73, 1–15.
  16. Podolak, I.; Galanty, A.; Sobolewska, D. Saponins as cytotoxic agents: A review. Phytochem. Rev. 2010, 9, 425–474.
  17. Sobolewska, D.; Galanty, A.; Grabowska, K.; Makowska-Wąs, J.; Wróbel-Biedrawa, D.; Podolak, I. Saponins as cytotoxic agents: An update (2010–2018). Part I-steroidal saponins. Phytochem. Rev. 2020, 19.
  18. Dimova, I.; Popivanov, G.; Djonov, V. Angiogenesis in cancer—General pathways and their therapeutic implications. JBUON 2014, 19, 15–21.
  19. Majnooni, M.B.; Fakhri, S.; Smeriglio, A.; Trombetta, D.; Croley, C.R.; Bhattacharyya, P.; Sobarzo-Sánchez, E.; Farzaei, M.H.; Bishayee, A. Antiangiogenic Effects of Coumarins against Cancer: From Chemistry to Medicine. Molecules 2019, 24, 4278.
  20. Simons, M.; Gordon, E.; Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 2016, 17, 611–625.
  21. Zhao, Y.; Adjei, A.A. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. oncologist 2015, 20, 660–673.
  22. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401–410.
  23. Lugano, R.; Ramachandran, M.; Dimberg, A. Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020, 77, 1745–1770.
  24. Mukherjee, A.; Basu, S.; Sarkar, N.; Ghosh, A. Advances in Cancer Therapy with Plant Based Natural Products. Curr. Med. Chem. 2001, 8, 1467–1486.
  25. Zheng, Q.; Li, X.; Cheng, X.; Cui, T.; Zhuo, Y.; Ma, W.; Zhao, X.; Zhao, P.; Liu, X.; Feng, W. Granulocyte-macrophage colony-stimulating factor increases tumor growth and angiogenesis directly by promoting endothelial cell function and indirectly by enhancing the mobilization and recruitment of proangiogenic granulocytes. Tumor Biol. 2017, 39.
  26. Fakhri, S.; Khodamorady, M.; Naseri, M.; Farzaei, M.H.; Khan, H. The ameliorating effects of anthocyanins on the cross-linked signaling pathways of cancer dysregulated metabolism. Pharmacol. Res. 2020, 159, 104895.
  27. Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 2011, 4, 51.
  28. Xue, C.; Xie, J.; Zhao, D.; Lin, S.; Zhou, T.; Shi, S.; Shao, X.; Lin, Y.; Zhu, B.; Cai, X. The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model. Cell Prolif. 2016, 50, e12307.
  29. Tsao, S.-M.; Hsia, T.-C.; Yin, M.-C. Protocatechuic Acid Inhibits Lung Cancer Cells by Modulating FAK, MAPK, and NF-κB Pathways. Nutr. Cancer 2014, 66, 1331–1341.
  30. de Bittencourt Pasquali, M.A.; Gelain, D.P.; Zeidán-Chuliá, F.; Pires, A.S.; Gasparotto, J.; Terra, S.R.; Moreira, J.C.F. Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cell. Signal. 2013, 25, 939–954.
  31. Sun, Y.; Zhang, L.; Zhang, M.; Li, R.; Li, Y.; Hu, X.; Wang, S.; Bao, Z. Characterization of three mitogen-activated protein kinases (MAPK) genes reveals involvement of ERK and JNK, not p38 in defense against bacterial infection in Yesso scallop Patinopecten yessoensis. Fish Shellfish. Immunol. 2016, 54, 507–515.
  32. Chen, H.-X.; Xu, X.-X.; Tan, B.-Z.; Zhang, Z.; Zhou, X.-D. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. Cell. Physiol. Biochem. 2017, 41, 933–946.
  33. Fakhri, S.; Moradi, S.Z.; DeLiberto, L.K.; Bishayee, A. Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies. Biochem. Pharmacol. 2022, 199, 114989.
  34. Ahmed, A.M. The dual role of oxidative stress in lung cancer. In Oxidative Stress in Lung Diseases; Springer: Berlin/Heidelberg, Germany, 2019; pp. 99–113.
  35. Quintero-Fabián, S.; Arreola, R.; Becerril-Villanueva, E.; Torres-Romero, J.C.; Arana-Argáez, V.; Lara-Riegos, J.; Ramírez-Camacho, M.A.; Alvarez-Sánchez, M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front. Oncol. 2019, 9, 1370.
  36. Olejarz, W.; Kubiak-Tomaszewska, G.; Chrzanowska, A.; Lorenc, T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int. J. Mol. Sci. 2020, 21, 5840.
  37. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039–2049.
  38. Rundhaug, J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005, 9, 267–285.
  39. Sakurai, T.; Kudo, M. Signaling Pathways Governing Tumor Angiogenesis. Oncology 2011, 81, 24–29.
  40. Tiwari, A.; Mukherjee, B.; Dixit, M. MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy. Curr. Cancer Drug Targets 2018, 18, 266–277.
  41. Pugh, C.W.; Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med. 2003, 9, 677–684.
  42. Clarke, S.J.; Sharma, R. Angiogenesis inhibitors in cancer-mechanisms of action. Aust. Prescr. 2006, 29.
  43. Al-Abd, A.M.; Alamoudi, A.J.; Abdel-Naim, A.B.; Neamatallah, T.A.; Ashour, O.M. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies—A review. J. Adv. Res. 2017, 8, 591–605.
  44. Qi, S.; Deng, S.; Lian, Z.; Yu, K. Novel Drugs with High Efficacy against Tumor Angiogenesis. Int. J. Mol. Sci. 2022, 23, 6934.
  45. Rahman, R.; Smith, S.; Rahman, C.; Grundy, R. Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma. J. Oncol. 2010, 2010, 251231.
  46. Oguntade, A.S.; Al-Amodi, F.; Alrumayh, A.; Alobaida, M.; Bwalya, M. Anti-angiogenesis in cancer therapeutics: The magic bullet. J. Egypt. Natl. Cancer Inst. 2021, 33, 1–11.
  47. Teleanu, R.I.; Chircov, C.; Grumezescu, A.M.; Teleanu, D.M. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J. Clin. Med. 2019, 9, 84.
  48. Eatock, M.; Tebbutt, N.; Bampton, C.; Strickland, A.; Valladares-Ayerbes, M.; Swieboda-Sadlej, A.; Van Cutsem, E.; Nanayakkara, N.; Sun, Y.-N.; Zhong, Z.; et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann. Oncol. 2013, 24, 710–718.
  49. Zhou, J.; Wang, L.; Peng, C.; Peng, F. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology. Front. Pharmacol. 2022, 13, 886198.
  50. Safarzadeh, E.; Shotorbani, S.S.; Baradaran, B. Herbal Medicine as Inducers of Apoptosis in Cancer Treatment. Adv. Pharm. Bull. 2014, 4, 421–427.
  51. Balunas, M.J.; Kinghorn, A.D. Drug discovery from medicinal plants. Life Sci. 2005, 78, 431–441.
  52. Sobolewska, D.; Michalska, K.; Podolak, I.; Grabowska, K. Steroidal saponins from the genus Allium. Phytochem. Rev. 2014, 15, 1–35.
  53. Weng, A.; Thakur, M.; Melzig, M.F.; Fuchs, H. Chemistry and pharmacology of saponins: Special focus on cytotoxic properties. Bot. Targets Ther. 2011, 1, 19–29.
  54. Biswas, T.; Dwivedi, U.N. Plant triterpenoid saponins: Biosynthesis, in vitro production, and pharmacological relevance. Protoplasma 2019, 256, 1463–1486.
  55. Ashour, A.S.; El Aziz, M.M.A.; Melad, A.S.G. A review on saponins from medicinal plants: Chemistry, isolation, and determination. J. Nanomed. Res. 2019, 7, 282–288.
  56. Challinor, V.L.; De Voss, J.J. Open-chain steroidal glycosides, a diverse class of plant saponins. Nat. Prod. Rep. 2013, 30, 429–454.
  57. Sparg, S.G.; Light, M.E.; Van Staden, J. Biological activities and distribution of plant saponins. J. Ethnopharmacol. 2004, 94, 219–243.
  58. Oleszek, W.; Hamed, A. Saponin-based surfactants. Surfactants Renew. Resour. 2010, 1, 239–251.
  59. Findlay, J.A.; Agarwal, V.K.; Moharir, Y.E. On the Saponins of the Starfish Asterias vulgaris. J. Nat. Prod. 1984, 47, 113–116.
  60. Nicolas, G.; Oulad-Ali, A.; Guillaume, D.; Lobstein, A.; Weniger, B.; Anton, R. Triterpenoid saponins from the root of Sideroxylon foetidissimum. Phytochemistry 1995, 38, 225–228.
  61. Woo, E.H.; Woo, W.S.; Chmurny, G.N.; Hilton, B.D. Melandrioside A, a Saponin from Melandrium firmum. J. Nat. Prod. 1992, 55, 786–794.
  62. Augustin, J.M.; Kuzina, V.; Andersen, S.B.; Bak, S. Molecular activities, biosynthesis and evolution of triterpenoid saponins. Phytochemistry 2011, 72, 435–457.
  63. Haralampidis, K.; Trojanowska, M.; Osbourn, A.E. Biosynthesis of Triterpenoid Saponins in Plants. In History and Trends in Bioprocessing and Biotransformation; Springer: Berlin/Heidelberg, Germany, 2002; Volume 75, pp. 31–49.
  64. Broberg, S.; Nord, L.I.; Kenne, L. Oligosaccharide sequences inQuillaja saponins by electrospray ionization ion trap multiple-stage mass spectrometry. J. Mass Spectrom. 2004, 39, 691–701.
  65. Üstündağ, G.; Mazza, G. Saponins: Properties, Applications and Processing. Crit. Rev. Food Sci. Nutr. 2007, 47, 231–258.
  66. Hussain, M.; Debnath, B.; Qasim, M.; Bamisile, B.S.; Islam, W.; Hameed, M.S.; Wang, L.; Qiu, D. Role of Saponins in Plant Defense against Specialist Herbivores. Molecules 2019, 24, 2067.
  67. Szakiel, A.; Pączkowski, C.; Henry, M. Influence of environmental abiotic factors on the content of saponins in plants. Phytochem. Rev. 2010, 10, 471–491.
  68. Sautour, M.; Mitaine-Offer, A.-C.; Lacaille-Dubois, M.-A. The Dioscorea genus: A review of bioactive steroid saponins. J. Nat. Med. 2007, 61, 91–101.
  69. Lu, Y.; Luo, J.; Kong, L. Steroidal alkaloid saponins and steroidal saponins from Solanum surattense. Phytochemistry 2011, 72, 668–673.
  70. Hayes, P.Y.; Jahidin, A.H.; Lehmann, R.; Penman, K.; Kitching, W.; De Voss, J.J. Asparinins, asparosides, curillins, curillosides and shavatarins: Structural clarification with the isolation of shatavarin V, a new steroidal saponin from the root of Asparagus racemosus. Tetrahedron Lett. 2006, 47, 8683–8687.
  71. Schmid, C.; Dawid, C.; Peters, V.; Hofmann, T. Saponins from European Licorice Roots (Glycyrrhiza glabra). J. Nat. Prod. 2018, 81, 1734–1744.
  72. Reichert, C.L.; Salminen, H.; Weiss, J. Quillaja Saponin Characteristics and Functional Properties. Annu. Rev. Food Sci. Technol. 2019, 10, 43–73.
  73. Shin, B.-K.; Kwon, S.W.; Park, J.H. Chemical diversity of ginseng saponins from Panax ginseng. J. Ginseng Res. 2015, 39, 287–298.
  74. Peng, D.; Wang, H.; Qu, C.; Xie, L.; Wicks, S.M.; Xie, J. Ginsenoside Re: Its chemistry, metabolism and pharmacokinetics. Chin. Med. 2012, 7, 1–6.
  75. Zheng, M.; Xin, Y.; Li, Y.; Xu, F.; Xi, X.; Guo, H.; Cui, X.; Cao, H.; Zhang, X.; Han, C. Ginsenosides: A Potential Neuroprotective Agent. BioMed Res. Int. 2018, 2018, 8174345.
  76. Bahrami, Y.; Zhang, W.; Chataway, T.; Franco, C.M.M. Structural Elucidation of Novel Saponins in the Sea Cucumber Holothuria lessoni. Mar. Drugs 2014, 12, 4439–4473.
  77. Dahmoune, B.; Bachari-Houma, F.; Chibane, M.; Jéhan, P.; Guegan, J.-P.; Dahmoune, F.; Aissou-Akrour, C.; Mouni, L.; Ferrières, V.; Hauchard, D. Saponin contents in the starfish Echinaster sepositus: Chemical characterization, qualitative and quantitative distribution. Biochem. Syst. Ecol. 2021, 96, 104262.
  78. Kun-Ya, W.; Ping-Lin, L.; Jing-Fan, S.; de Voogd, N.J.; Xu-Li, T.; Guo-Qiang, L. Four new polyhydroxylated steroids from the South Sea sponge Plakortis sp. Chin. J. Nat. Med. 2020, 18, 844–849.
  79. Bahrami, Y.; Zhang, W.; MM Franco, C. Distribution of Saponins in the Sea Cucumber Holothuria lessoni; the Body Wall Versus the Viscera, and Their Biological Activities. Mar. Drugs 2018, 16, 423.
  80. Najjar-Tabrizi, R.; Javadi, A.; Sharifan, A.; Chew, K.W.; Lay, C.-H.; Show, P.L.; Jafarizadeh-Malmiri, H.; Berenjian, A. Hydrothermally extraction of saponin from Acanthophyllum glandulosum root—Physico-chemical characteristics and antibacterial activity evaluation. Biotechnol. Rep. 2020, 27, e00507.
  81. Sonfack, G.; Fossi Tchinda, C.; Simo, I.K.; Bitchagno, G.T.M.; Nganou, B.K.; Çelik, İ.; Tene, M.; Funda Görkem, S.; Opatz, T.; Penlap Beng, V. Saponin with antibacterial activity from the roots of Albizia adianthifolia. Nat. Prod. Res. 2021, 35, 2831–2839.
  82. Sharma, P.; Tyagi, A.; Bhansali, P.; Pareek, S.; Singh, V.; Ilyas, A.; Mishra, R.; Poddar, N.K. Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives. Food Chem. Toxicol. 2021, 150, 112075.
  83. Yang, C.-R.; Zhang, Y.; Jacob, M.R.; Khan, S.I.; Li, X.-C. Antifungal Activity of C-27 Steroidal Saponins. Antimicrob. Agents Chemother. 2006, 50, 1710–1714.
  84. Favel, A.; Steinmetz, M.; Regli, P.; Vidal-Ollivier, E.; Elias, R.; Balansard, G. In Vitro Antifungal Activity of Triterpenoid Saponins. Planta Med. 1994, 60, 50–53.
  85. Germonprez, N.; Van Puyvelde, L.; Maes, L.; Van Tri, M.; De Kimpe, N. New pentacyclic triterpene saponins with strong anti-leishmanial activity from the leaves of Maesa balansae. Tetrahedron 2004, 60, 219–228.
  86. Banerjee, S.; Mukherjee, N.; Gajbhiye, R.L.; Mishra, S.; Jaisankar, P.; Datta, S.; Das Saha, K. Intracellular anti-leishmanial effect of Spergulin-A, a triterpenoid saponin of Glinus oppositifolius. Infect. Drug Resist. 2019, ume 12, 2933–2942.
  87. Zhou, Q.; Sun, H.J.; Liu, S.M.; Jiang, X.H.; Wang, Q.Y.; Zhang, S.; Yu, D.H. Anti-inflammation effects of the total saponin fraction from Dioscorea nipponica Makino on rats with gouty arthritis by influencing MAPK signalling pathway. BMC Complement. Med. Ther. 2020, 20, 1–13.
  88. Yao, Y.; Yang, X.; Shi, Z.; Ren, G. Anti-inflammatory activity of saponins from quinoa (Chenopodium quinoa Willd.) seeds in lipopolysaccharide-stimulated RAW 264.7 macrophages cells. J. Food Sci. 2014, 79, H1018–H1023.
  89. Chen, Y.; Miao, Y.; Huang, L.; Li, J.; Sun, H.; Zhao, Y.; Yang, J.; Zhou, W. Antioxidant activities of saponins extracted from Radix Trichosanthis: An in vivo and in vitro evaluation. BMC Complement. Altern. Med. 2014, 14, 86.
  90. Zhou, N.; Tang, Y.; Keep, R.F.; Ma, X.; Xiang, J. Antioxidative effects of Panax notoginseng saponins in brain cells. Phytomedicine 2014, 21, 1189–1195.
  91. Singh, D.; Chaudhuri, P.K. Structural characteristics, bioavailability and cardioprotective potential of saponins. Integr. Med. Res. 2018, 7, 33–43.
  92. Sun, A.; Xu, X.; Lin, J.; Cui, X.; Xu, R. Neuroprotection by Saponins. Phytother. Res. 2014, 29, 187–200.
  93. Man, S.; Gao, W.; Zhang, Y.; Huang, L.; Liu, C. Chemical study and medical application of saponins as anti-cancer agents. Fitoterapia 2010, 81, 703–714.
  94. Raju, J.; Mehta, R. Cancer Chemopreventive and Therapeutic Effects of Diosgenin, a Food Saponin. Nutr. Cancer 2008, 61, 27–35.
  95. Lee, K.J.; Choi, C.Y.; Chung, Y.C.; Kim, Y.S.; Ryu, S.Y.; Roh, S.H.; Jeong, H.G. Protective effect of saponins derived from roots of Platycodon grandiflorum on tert-butyl hydroperoxide-induced oxidative hepatotoxicity. Toxicol. Lett. 2004, 147, 271–282.
  96. Rajput, S.S.; Soni, K.K.; Saxena, R. Pharmacology and phytochemistry of saponin isolated from Aloe vera for wound healing activity. Asian J. Chem. 2009, 21, 1029–1032.
  97. Sevimli-Gür, C.; Onbaşılar, İ.; Atilla, P.; Genç, R.; Çakar, N.; Deliloğlu-Gürhan, I.; Bedir, E. In vitro growth stimulatory and in vivo wound healing studies on cycloartane-type saponins of Astragalus genus. J. Ethnopharmacol. 2011, 134, 844–850.
  98. Wang, J.-R.; Zhou, H.; Jiang, Z.-H.; Wong, Y.F.; Liu, L. In Vivo Anti-inflammatory and Analgesic Activities of a Purified Saponin Fraction Derived from the Root of Ilex pubescens. Biol. Pharm. Bull. 2008, 31, 643–650.
  99. Shu, P.-P.; Li, L.-X.; He, Q.-M.; Pan, J.; Li, X.-L.; Zhu, M.; Yang, Y.; Qu, Y. Identification and quantification of oleanane triterpenoid saponins and potential analgesic and anti-inflammatory activities from the roots and rhizomes of Panax stipuleanatus. J. Ginseng Res. 2020, 45, 305–315.
  100. Meng, M.; Yue, Z.; Chang, L.; Liu, Y.; Hu, J.; Song, Z.; Tang, Z.; Zhou, R.; Wang, C. Anti-Rheumatoid Arthritic Effects of Paris Saponin VII in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes and Adjuvant-Induced Arthritis in Rats. Front. Pharmacol. 2021, 12.
  101. Choi, J.; Huh, K.; Kim, S.-H.; Lee, K.-T.; Park, H.-J.; Han, Y.N. Antinociceptive and anti-rheumatoidal effects of Kalopanax pictus extract and its saponin components in experimental animals. J. Ethnopharmacol. 2001, 79, 199–204.
  102. Singh, D.; Singh, B.; Goel, R.K. Role of saponins for the anticonvulsant effect of adventitious roots of Ficus religiosa. Pharm. Biol. 2012, 50, 816–822.
  103. Abaci, H.; Akagac, G.; Nalbantsoy, A.; Sarikahya, N.B. A hederagenin-type triterpene saponin, sumbulianoside a from Cephalaria sumbuliana and its potent immunomodulatory activity against seasonal flu virus H3N2. Nat. Prod. Res. 2021, 36, 2495–2503.
  104. Sarikahya, N.B.; Nalbantsoy, A.; Top, H.; Gokturk, R.S.; Sumbul, H.; Kirmizigul, S. Immunomodulatory, hemolytic and cytotoxic activity potentials of triterpenoid saponins from eight Cephalaria species. Phytomedicine 2018, 38, 135–144.
  105. Wang, P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines 2021, 9, 222.
  106. Sharma, R.; Palanisamy, A.; Dhama, K.; Mal, G.; Singh, B.; Singh, K.P. Exploring the possible use of saponin adjuvants in COVID-19 vaccine. Hum. Vaccines Immunother. 2020, 16, 2944–2953.
  107. Waite, D.C.; Jacobson, E.W.; Ennis, F.A.; Edelman, R.; White, B.; Kammer, R.; Anderson, C.; Kensil, C.R. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19, 3957–3967.
  108. Khan, N.; Akhtar, M.S.; Khan, B.A.; Braga, V.D.A.; Reich, A. Antiobesity, hypolipidemic, antioxidant and hepatoprotective effects of Achyranthes aspera seed saponins in high cholesterol fed albino rats. Arch. Med. Sci. 2015, 6, 1261–1271.
  109. Chen, C.; Han, X.; Dong, P.; Li, Z.; Yanagita, T.; Xue, C.; Zhang, T.; Wang, Y. Sea cucumber saponin liposomes ameliorate obesity-induced inflammation and insulin resistance in high-fat-diet-fed mice. Food Funct. 2017, 9, 861–870.
  110. Lu, F.-r.; Shen, L.; Qin, Y.; Gao, L.; Li, H.; Dai, Y. Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin. J. Integr. Med. 2008, 14, 56–60.
  111. Khatik, G.L.; Suttee, A. The Possible Role of Saponin in Type-II Diabetes—A Review. Curr. Diabetes Rev. 2021, 17, 107–121.
  112. Oakenfull, D. Saponins in the treatment of hypercholesterolemia. In Handbook of Lipids in Human Nutrition; CRC Press: Boca Raton, FL, USA, 2020; pp. 107–112.
  113. Chen, M.; Long, Z.; Wang, Y.; Liu, J.; Pian, H.; Wang, L.; Chen, Z. Protective effects of saponin on a hypertension target organ in spontaneously hypertensive rats. Exp. Ther. Med. 2012, 5, 429–432.
  114. Sudheendra, A.T.; Shenoy, R.; Taranalli, A.D. Evaluation of saponin rich fraction of Trigonella foenum graecum for antihypertensive activity. Pharmacol. Online 2009, 1, 1229–1233.
  115. Siddiqi, M.H.; Ahn, S.; Kang, S.; Kim, Y.-J.; Sathishkumar, N.; Yang, D.-U.; Yang, D.-C. Ginseng saponins and the treatment of osteoporosis: Mini literature review. J. Ginseng Res. 2013, 37, 261–268.
  116. Dutta, A.; Ghoshal, A.; Mandal, D.; Mondal, N.B.; Banerjee, S.; Sahu, N.P.; Mandal, C. Racemoside A, an anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani. J. Med. Microbiol. 2007, 56, 1196–1204.
  117. Khan, M.I.; Ahhmed, A.; Shin, J.H.; Baek, J.S.; Kim, M.Y.; Kim, J.D. Green Tea Seed Isolated Saponins Exerts Antibacterial Effects against Various Strains of Gram Positive and Gram Negative Bacteria, a Comprehensive Study In Vitro and In Vivo. Evid.-Based Complement. Altern. Med. 2018, 2018, 3486106.
  118. Sur, P.; Chaudhuri, T.; Vedasiromoni, J.; Gomes, A.; Ganguly, D. Antiinflammatory and antioxidant property of saponins of tea root extract. Phytother. Res. 2001, 15, 174–176.
  119. Mostafa, A.; Sudisha, J.; El-Sayed, M.; Ito, S.-I.; Ikeda, T.; Yamauchi, N.; Shigyo, M. Aginoside saponin, a potent antifungal compound, and secondary metabolite analyses from Allium nigrum L. Phytochem. Lett. 2013, 6, 274–280.
  120. Li, H.-X.; Han, S.-Y.; Ma, X.; Zhang, K.; Wang, L.; Ma, Z.-Z.; Tu, P.-F. The saponin of red ginseng protects the cardiac myocytes against ischemic injury in vitro and in vivo. Phytomedicine 2012, 19, 477–483.
  121. Li, C.; Yang, J.; Yu, S.; Chen, N.; Xue, W.; Hu, J.; Zhang, D. Triterpenoid Saponins with Neuroprotective Effects from the Roots of Polygala tenuifolia. Planta Med. 2008, 74, 133–141.
  122. Meng, J.; Hu, X.; Zhang, T.; Dong, P.; Li, Z.; Xue, C.; Chang, Y.; Wang, Y. Saponin from sea cucumber exhibited more significant effects than ginsenoside on ameliorating high fat diet-induced obesity in C57BL/6 mice. MedChemComm 2018, 9, 725–734.
  123. Nalbantsoy, A.; Nesil, T.; Yılmaz-Dilsiz, Ö.; Aksu, G.; Khan, S.; Bedir, E. Evaluation of the immunomodulatory properties in mice and in vitro anti-inflammatory activity of cycloartane type saponins from Astragalus species. J. Ethnopharmacol. 2012, 139, 574–581.
  124. Pal, D.; Sannigrahi, S.; Mazumder, U.K. Analgesic and anticonvulsant effects of saponin isolated from the leaves of Clerodendrum infortunatum Linn. in mice. Experiment 2009, 47.
  125. Kianian, F.; Marefati, N.; Boskabady, M.; Ghasemi, S.Z.; Boskabady, M.H. Pharmacological Properties of Allium cepa, preclinical and clinical evidences; a review. Iran. J. Pharm. Res. 2021, 20, 107.
  126. Steels, E.; Steele, M.; Harold, M.; Coulson, S. Efficacy of a proprietary Trigonella foenum-graecum L. de-husked seed extract in reducing menopausal symptoms in otherwise healthy women: A double-blind, randomized, placebo-controlled study. Phytother. Res. 2017, 31, 1316–1322.
  127. Wang, R.; Wang, M.; Zhou, J.; Wu, D.; Ye, J.; Sun, G.; Sun, X. Saponins in Chinese Herbal Medicine Exerts Protection in Myocardial Ischemia–Reperfusion Injury: Possible Mechanism and Target Analysis. Front. Pharmacol. 2021, 11, 570867.
  128. Verma, N.; Usman, K.; Patel, N.; Jain, A.; Dhakre, S.; Swaroop, A.; Bagchi, M.; Kumar, P.; Preuss, H.G.; Bagchi, D. A multicenter clinical study to determine the efficacy of a novel fenugreek seed (Trigonella foenum-graecum) extract (Fenfuro™) in patients with type 2 diabetes. Food Nutr. Res. 2016, 60, 32382.
  129. Fan, W.; Huang, Y.; Zheng, H.; Li, S.; Li, Z.; Yuan, L.; Cheng, X.; He, C.; Sun, J. Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms. Biomed. Pharmacother. 2020, 132, 110915.
  130. He, Y.; Yang, J.; Lv, Y.; Chen, J.; Yin, F.; Huang, J.; Zheng, Q. A Review of Ginseng Clinical Trials Registered in the WHO International Clinical Trials Registry Platform. BioMed Res. Int. 2018, 2018, 1843142.
  131. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  132. El-Kenawi, A.E.; El-Remessy, A.B. Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol. 2013, 170, 712–729.
  133. Munir, S.; Shah, A.A.; Shahid, M.; Ahmed, M.S.; Shahid, A.; Rajoka, M.S.; Akash, M.S.H.; Akram, M.; Khurshid, M. Anti-angiogenesis Potential of Phytochemicals for the Therapeutic Management of Tumors. Curr. Pharm. Des. 2020, 26, 265–278.
  134. Ribatti, D.; Vacca, A.; Nico, B.; De Falco, G.; Montaldo, P.G.; Ponzoni, M. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur. J. Cancer 2002, 38, 750–757.
  135. Wang, F.; Cao, Y.; Liu, H.-Y.; Xu, S.-F.; Han, R. Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells. J. Asian Nat. Prod. Res. 2003, 5, 121–129.
  136. Subbaraj, G.K.; Kumar, Y.S.; Kulanthaivel, L. Antiangiogenic role of natural flavonoids and their molecular mechanism: An update. Egypt. J. Intern. Med. 2021, 33, 29.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mohammad Bagher Majnooni
,
Sajad Fakhri
,
Syed Mustafa Ghanadian
,
Gholamreza Bahrami
,
Kamran Mansouri
,
Amin Iranpanah
,
Mohammad Hosein Farzaei
,
Mahdi Mojarrab
View Times: 499
Revisions: 3 times (View History)
Update Date: 24 Mar 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback